You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

The Role of Trastuzumab (Herceptin) in the Treatment of Women with HER2/neu-overexpressing Metastatic Breast Cancer

Research Question(s)

In women with HER2/neu-overexpressing breast cancer:

  1. Compared with adjuvant or neoadjuvant chemotherapy alone, does trastuzumab in combination with chemotherapy improve clinically meaningful outcomes (overall response rate, time-to-disease-progression, overall survival, toxicity, or quality of life)?
  2. Compared with placebo or observation, does single-agent trastuzumab adjuvant or neoadjuvant therapy improve clinically meaningful outcomes?
  3. What is the best way to identify women who will benefit from adjuvant or neoadjuvant trastuzumab therapy?
  4. What are the adverse events associated with adjuvant or neoadjuvant trastuzumab therapy?
  5. What are the optimal dose, schedule, and duration for adjuvant trastuzumab therapy?
pdf download pebc1-15f.pdf
Modality: 

Immunotherapy

PEBC: 

PEBC

Guideline Identifier: 

1-15 Version 3

Cancer Continuum: 

Treatment

Cancer Type: 

Breast

Type of Content: 

Guidelines & Advice

Clinical

Authors:  Breast Cancer Disease Site Group Universal Date:  2011-09-15 00:00:00